Overweight vs Obesity: The Line FDA Drew for Ads

what exactly did fda say about obesity versus overweight?

FDA settled the question in the preamble to its January 2000 structure/function rule, the regulation that still governs supplement marketing today. Responding to industry comments, the agency wrote that "obesity is a disease, and that obesity claims are not acceptable structure/function claims," while being overweight — more than one's ideal weight but less than obese — is not a disease at all, according to FDA's 2000 final rule. That single paragraph, printed at 65 FR 1000, page 1027, is what lets a weight-loss offer exist as a supplement claim instead of an unapproved drug claim.

A structure/function claim, a statement describing how a supplement affects the body rather than a disease, is the only lawful claim type available here absent an authorized health claim. FDA's overweight/obesity split means a formula can describe support for a weight-management goal without describing treatment of a diagnosed condition. Nothing in the cited language ties "overweight" to a number — no BMI, no body-fat percentage, no clinical cutoff appears anywhere in it.

Disease status decides the claim, not the scale.

No authorized or qualified health claim exists for weight loss at all, which is one reason the line matters so much — there is no FDA-approved weight-loss supplement claim to fall back on if the structure/function wording fails.

why does that distinction sit in the preamble instead of the regulation?

It sits in the preamble because FDA wrote it as agency interpretation answering public comments, not as codified rule text. We checked the operative text of 21 CFR 101.93 against the preamble language, and the overweight/obesity split appears only in the commentary — never in the section a court would treat as binding law.

That gap matters because the preamble also resolves only one of two independent questions. FDA's rule decides whether wording makes a product an unapproved new drug claim rather than a lawful supplement claim. It says nothing about whether the claim is truthful advertising, and that's the Federal Trade Commission's separate lane.

Here's the point most media buyers get backward: clearing FDA's disease-claim test is the easier bar, not the harder one. FDA enforcement in this vertical runs through warning letters against a fairly narrow set of disease-adjacent phrases, while FTC enforcement reaches any weight-loss efficacy claim at all, disease-related or not, and demands competent and reliable scientific evidence behind it. An offer that never mentions obesity can still sit under an open FTC investigation.

which words and images push a weight loss ad onto the obesity side?

Specific vocabulary and specific imagery push an ad onto the obesity side — general weight-loss language does not. FDA reviewed "use as part of your weight loss plan" and "appetite suppressant" directly in its 2000 rule and let both through, writing that "weight loss plans are not so narrowly associated with disease treatment" that a plan reference becomes a disease claim. "Appetite suppressant" only crosses the line in a context that implies use for obesity specifically, so context decides the outcome, not the words themselves.

Two routes bypass the wording entirely. Under 21 CFR 101.93(g)(2)(iv), a product name alone can create a disease claim, and so can pictures, vignettes or symbols with zero sentences of body copy attached. A product named for obesity, or a page built on clinically obese before/after imagery, is the violation — the surrounding paragraph doesn't get a chance to save it.

We counted all seven of the claims FTC's Gut Check guide labels as presumptively deceptive against the creative devices still running in the niche, and four map onto standard hooks one-to-one.

The no-effort and absorption hooks are the backbone of formats we've tracked elsewhere. The ice hack framing leans on a mechanism story that implies exactly the no-effort category FTC pre-labeled as always false.

The blue tonic ritual format runs the same risk through a different device — a single daily action standing in for the diet-and-exercise disclosure the underlying study would actually require.

The 7-second ritual format compresses the same no-effort promise into a single micro-habit, which is precisely the shape FTC's guide had in mind when it wrote the claim down in 2014.

does staying on the overweight side actually protect the campaign?

No — staying on the overweight side of FDA's line protects you from one kind of exposure and leaves several others wide open. The same 2000 rule that draws the obesity distinction also lets a disease claim appear with zero words of body copy, through the product's name or through pictures, vignettes or symbols under 21 CFR 101.93(g)(2)(iv). A landing page with careful copy and a clinically obese before/after photo can still fail on the imagery alone.

The disclaimer doesn't rescue a claim that has already crossed the line, either. FTC's own Health Products Compliance Guidance treats a disclaimer that is "directly contradictory" to an express claim as "ineffective to negate" it, and a separate example in the same guidance rejects burying a no-clinical-study line in the fine print of Terms and Conditions when the headline reads like proven science.

A compliant headline next to a disease-coded image is still a disease claim.

what does the ftc still require even when fda is satisfied?

FTC still requires competent and reliable scientific evidence for the underlying efficacy claim, full stop, regardless of how FDA would classify the wording. That standard generally means randomized, controlled human clinical testing behind the claim — not a customer survey, not an ingredient study run at a different dose, not a study your competitor ran on a different formula.

FTC's Gut Check guide defines "substantial weight loss" precisely: a pound a week for more than four weeks, or more than 15 pounds total, in any time period. Paraphrasing around the number doesn't help — the guide warns that dress-size references, inch measurements and body-fat percentage claims can convey the same message without a single digit printed on the page.

This is where testimonial-driven landers actually fail, and it's a narrower trap than most advertisers expect. FTC's Example 41 describes a before-and-after ad quoting a woman who lost 16 pounds in eight weeks, with a fine-print "results not typical" asterisk sitting against an underlying study that averaged only four pounds over placebo — FTC called the disclosure inadequate and prescribed the actual fix, a prominent, adjacent statement of the real study average, not a hedge buried at the bottom of the page. The same guidance carries a second trap that catches nearly every supplement RCT: if the clinical study behind your claim included diet and exercise as part of the protocol, the ad has to say so, because FTC's Example 8 treats omitting that fact as the violation, not an oversight.

Reviews carry the same substantiation duty as the headline claim. FTC's first case over fake paid reviews on an independent retail site was a weight-loss offer — Cure Encapsulations settled in 2019 after paying a third-party site to post fake reviews for a garcinia cambogia supplement, layered on top of the underlying unsubstantiated efficacy claims.

how do bmi references, clinical framing and glp-1 comparisons change the read?

Each one moves the copy further from the overweight side of FDA's line, for a different reason. A BMI number or a named diagnostic threshold points at a measurable clinical state, not the vague "more than one's ideal weight" phrase FDA actually used in 2000. Clinical framing — study citations, lab coats, "clinically proven" language — works because it targets exactly the audience FTC named in its own Gut Check guide: "Misleading ads for weight loss products target consumers desperate for results."

GLP-1 comparisons carry the sharpest exposure of the three. Positioning a supplement as "like Ozempic" or a "natural GLP-1" reaches straight into 21 CFR 101.93(g)(2)(vi), the criterion that treats a product presented as a substitute for a drug therapy as a disease claim, and it separately trips Google's Unapproved substances rule, which bars products that imply they're as effective as prescription drugs regardless of any claims of legality.

Here's the one thing on this page we couldn't nail down with a number: whether FDA ties "overweight" to any specific BMI threshold outside this preamble language. The rule's own text stops at "more than one's ideal weight but less than obese" with no figure attached, and the CDC and NIH pages that would carry an official BMI classification were unreachable when we checked. Settling it means pulling CDC's adult BMI categories directly and confirming FDA has never cross-referenced them in later guidance.

A number FDA never wrote is not a safe harbor you can borrow.

what should a media buyer check on an offer's lander before running it?

Check five things before spend starts, in this order: the product name, the imagery, the disclosure stack, the platform-specific targeting rules, and the supplier's FDA history. Miss any one of them and a compliant headline won't save the campaign.

Google's own definition of what fails is worth keeping next to that checklist: the platform's Misrepresentation policy is written to catch "claims that entice the user with an improbable result (even if this result is possible) as the likely outcome a user can expect," per Google's Unreliable claims policy — meaning a technically true best case, presented as the norm, still fails. You get seven days' warning before suspension under that policy, more room than FDA or FTC give you once a warning letter or complaint lands.

• Your product name and domain — does either reference obesity, a disease name, or an implied cure, which 21 CFR 101.93(g)(2)(iv)(A) treats as a claim on its own?
• Your before/after imagery — is the "before" photo clinically obese, and does any visual promise a specific outcome within a set timeframe without a disclaimer?
• Your study disclosure — if the clinical study behind the claim used diet and exercise, does the page say so, and if a testimonial shows more than 15 pounds lost, is the real study average shown with equal prominence?
• Your platform targeting — is the audience gated 18 and older, and does a guaranteed-results claim carry an accessible refund policy?
• Your supplier's history — has the exact product, or the manufacturer behind it, appeared on [FDA's tainted weight loss products list](/niches/fda-s-tainted-weight-loss-list-is-a-supplier-risk)?

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Teeth and Dental VSL Intelligence, Gut Health VSL Intelligence, How Money Is Actually Made in Nutra — Four Roles, Four Economics, Peptide Offers: What's Running, and the Rules That Govern Them, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.